These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1347520)

  • 21. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
    Runnebaum B; Grunwald K; Rabe T
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1963-8. PubMed ID: 1605286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilest--a combined OC.
    Drug Ther Bull; 1991 Dec; 29(26):103-4. PubMed ID: 1790761
    [No Abstract]   [Full Text] [Related]  

  • 23. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol).
    de Andrade RP
    Int J Fertil; 1989 Sep; 34 Suppl():22-30. PubMed ID: 2576253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Light and electron microscopy changes in the endometrium caused by the administration of a norgestimate-containing oral contraceptive (Cilest)].
    Rabe T; Leppien G; Kiesel L; Runnebaum B; Heinrich D; Johannisson E; Ludwig H
    Geburtshilfe Frauenheilkd; 1986 Dec; 46(12):883-91. PubMed ID: 3817409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
    Janaud A; Rouffy J; Upmalis D; Dain MP
    Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral contraceptives and blood coagulation.
    Bonnar J; Sabra AM
    J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
    Dieben TO; op ten Berg MT; Coelingh Bennink HJ
    Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supportive European data on a new oral contraceptive containing norgestimate.
    Becker H
    Acta Obstet Gynecol Scand Suppl; 1990; 152():33-9. PubMed ID: 2189283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian function during low-dose oral contraceptive use.
    Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
    Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for new oral contraceptive dosing.
    Williams JK
    Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Stone S
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():117-21. PubMed ID: 8260969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
    Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
    Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.